Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

New Collaboration with Leading Researchers having Clinical Experience with Antimicrobials that are Biological Basis for Aganocide Compounds

EMERYVILLE, Calif., April 22 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class, potent, well-tolerated products to treat and prevent a wide range of infections with low chance of developing drug resistance, today announced an exclusive agreement with Professors Markus Nagl M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria. The agreement was entered into to advance the development of NovaBay's Aganocide compounds by integrating extensive and on-going clinical work at the university with NovaBay's development program.

Professors Gottardi and Nagl have conducted extensive clinical research and have patented and published widely for many years on the use of N-chlorotaurine (NCT), a natural antimicrobial produced by the body's white blood cells. NovaBay's Aganocide compounds are synthetic analogs of NCT that maintain or enhance the biological activity of the natural compound while adding pharmaceutically acceptable stability. Professors Gottardi and Nagl have pioneered the exploratory use of NCT compounds in humans in a number of indications that overlap with and even go beyond those for which NovaBay's Aganocide compounds are currently being developed.

Under the terms of the agreement, NovaBay will fund ongoing research in the laboratories of Professors Gottardi and Nagl at the Medical University of Innsbruck and NovaBay will have access to past and future data generated in human clinical trials by Professors Nagl, Gottardi and their collaborators. These data are expected to support many of the indications being pursued by NovaBay and its partners. For instan
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
(Date:5/4/2015)... , May 4, 2015 DePuy Synthes CMF* ... Repair, the first commercially available biosynthesized dural replacement derived ... is a part of the DePuy Synthes Companies of ... tissue membrane that covers and protects the brain and ... to allow surgeons to access the brain. A dural ...
(Date:5/4/2015)... -- The board of directors of Eli Lilly and Company (NYSE: ... quarter of 2015 of $0.50 per share on outstanding common ... 2015, to shareholders of record at the close of business ... Lilly is a global healthcare leader that unites caring with ... We were founded more than a century ago by a ...
Breaking Medicine Technology:Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... BOZEN, Sud-Tirol, Italy , July 20, 2010 ... rights in Spain and Portugal to world-leading IV,Therapy company ... at Vall d,Hebron University Hospital in Barcelona in November,2010 . ... "We are ...
... , WILMINGTON, Del. , July 20 ... Be Heard… Living With Depression contest, ... Bipolar Support Alliance (DBSA), encourages people with depressive symptoms of ... depression) to share their stories of success.  Submissions are now ...
Cached Medicine Technology:Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 2Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 3Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 4National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 2National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 3National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 4National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 5National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 6National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 7
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes ... KissSafe™ is the first personal hygiene product dedicated ... adding fresh breath appeal. KissSafe™ contains an FDA-approved ... in the mouth and oral cavity before and ... possess additional wellness benefits. KissSafe’s proprietary prevent-tech will ...
(Date:5/4/2015)... In a continuing effort to remain a leading ... the founder of Choices Recovery in South Bend, IN, ... the Oscars” celebration held on February 21st, 2015, ... the luxurious Beverly Hilton Hotel. , Organized by ... placement in TV and film, this daylong event gathered ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Getting ... to manage their health is critical to achieving the ... and reducing costs, but this will require a shift ... change also demands that health systems move beyond their ... who took part in the third live meeting of ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3
... , TAMPA, Fla., Nov. 4 ... today its SNP Model of Care program to assist Special ... Medicare Improvements for Patients and Providers Act of 2008 (MIPPA). ... with Health Integrated will install a cost-effective, rapidly deployable program ...
... New ... orthopedic and sport uses. , ... San Diego, CA (PRWEB) November 4, 2009 -- BetterBraces.com, the sports bracing ... The new site continues BetterBraces.com commitment to provide customers with top quality braces and ...
... successes, especially for those with good lung function , ... 100 percent for people with early-stage lung cancer and ... radiosurgery using CyberKnife, according to a new study funded ... people with small lung tumors calls for surgical removal ...
... NEW YORK, Nov. 4 Vitech Systems Group, ... benefits administration, announced today that the Milwaukee County ... Vitech,s web-based customer self-service solution. This new self-service ... retired employees of Milwaukee County to receive real-time ...
... study accepted for publication in The Endocrine Society,s Journal ... quickly, as compared to slowly, curtails the release of hormones ... The decreased release of these hormones, can often lead to ... can lead to food overconsumption and obesity, and in fact ...
... ... On Mandatory Sleep Apnea Testing And "Successful Treatment", It Is Practically ... More Than 60% Of Sleep Apnea Patients Can Not Tolerate The ... Commercial Pilots And Drivers May Forever Lose Their Pilot,s Or Driver,s ...
Cached Medicine News:Health News:Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 2Health News:Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 3Health News:The Sports Bracing and Therapy Experts Re-Launch Website BetterBraces.com 2Health News:Focused Radiation May Help Some With Lung Cancer 2Health News:Milwaukee County Employees' Retirement System (MCERS) Goes Live with V3 Self-Service 2Health News:New scientific study indicates that eating quickly is associated with overeating 2Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 2Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 3Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 4Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 5
... Supplemental Confirmatory (Western Blot): The Genetic Systems ... test for the detection of antibodies to HIV-1. ... strain of HIV-1 grown in the CEM cell ... is devoid of HLA Class ll antigens, helps ...
... Screening: The Procleix System has added ... the nation's blood supply. It utilizes innovative ... and a unique nucleic acid amplification technique ... can simultaneously detect the presence of HIV-1 ...
... Diagnostic, Non-Donor Screen. Vironostika HIV assays provide ... additional testing and confirmation. Vironostika HIV-1 ... for the detection of antibody to HIV-1 ... Oral Fluid Vironostika HIV-1 Microelisa System ...
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
Medicine Products: